Mersana Competitors

MRSN Stock  USD 0.46  0.01  2.22%   
Mersana Therapeutics competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Mersana Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mersana Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mersana Therapeutics Correlation with its peers.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Mersana Therapeutics competition on your existing holdings.
  
As of the 14th of March 2025, Return On Equity is likely to grow to 7.64, while Return On Tangible Assets are likely to drop (0.50). At this time, Mersana Therapeutics' Total Assets are very stable compared to the past year. As of the 14th of March 2025, Non Current Assets Total is likely to grow to about 10.9 M, while Net Tangible Assets are likely to drop about 73.5 M.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mersana Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.020.499.64
Details
Intrinsic
Valuation
LowRealHigh
0.091.9011.05
Details
10 Analysts
Consensus
LowTargetHigh
5.696.256.94
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.22-0.18-0.17
Details

Mersana Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mersana Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mersana and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mersana Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ABOSTERN
INZYTERN
CGEMABOS
CGEMTERN
HOOKDAWN
CGEMINZY
  
High negative correlations   
RLAYTHRX
CGEMTHRX
THRXHOOK
THRXDAWN
THRXXFOR
THRXINZY

Risk-Adjusted Indicators

There is a big difference between Mersana Stock performing well and Mersana Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mersana Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TERN  2.98 (0.73) 0.00 (0.86) 0.00 
 5.03 
 20.46 
AMLX  3.89 (0.14) 0.00 (0.24) 0.00 
 7.20 
 21.45 
ABOS  2.98 (0.62) 0.00 (0.71) 0.00 
 6.57 
 19.77 
INZY  4.18 (0.96) 0.00 (0.78) 0.00 
 7.72 
 38.13 
XFOR  7.68  0.33  0.05 (3.91) 7.77 
 26.42 
 68.45 
DAWN  2.64 (0.45) 0.00 (0.61) 0.00 
 4.59 
 22.86 
HOOK  3.70 (0.96) 0.00 (5.10) 0.00 
 7.00 
 32.80 
THRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
CGEM  2.63 (0.36) 0.00 (0.67) 0.00 
 5.13 
 15.27 
RLAY  4.28  0.02  0.00 (0.13) 0.00 
 7.42 
 26.72 

Cross Equities Net Income Analysis

Compare Mersana Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
TERN(17.7 M)(17.7 M)(17.7 M)(17.7 M)(17.7 M)(17.7 M)(17.7 M)(17.7 M)(17.7 M)(68.8 M)(40.6 M)(50.2 M)(60.3 M)(90.2 M)(81.2 M)(85.2 M)
ABOS(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.9 M)(7.3 M)(181.7 M)(40.5 M)(52.4 M)(47.1 M)(49.5 M)
INZY(7 M)(7 M)(7 M)(7 M)(7 M)(7 M)(7 M)(7 M)(7 M)(18.6 M)(55.8 M)(56.4 M)(65.4 M)(71.2 M)(102 M)(96.9 M)
XFOR(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(23 M)(33.9 M)(43 M)(56.6 M)(62.1 M)(88.7 M)(93.9 M)(101.2 M)(91.1 M)(95.6 M)
DAWN(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(14.7 M)(40.5 M)(70.4 M)(132.2 M)(188.9 M)(95.5 M)(100.3 M)
HOOK(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(16.2 M)(34.1 M)(33.8 M)(75.7 M)(65.1 M)(81.6 M)(43.5 M)(45.7 M)
CGEM(704.7 K)(704.7 K)(704.7 K)(704.7 K)(130.5 K)(109.5 K)(316.7 K)(14.2 M)(14.2 M)(20 M)(50.8 M)(65 M)111.2 M(153.2 M)(167.4 M)(159 M)
RLAY(48.8 M)(48.8 M)(48.8 M)(48.8 M)(48.8 M)(48.8 M)(48.8 M)(48.8 M)(48.8 M)(66.5 M)(49 M)(496.8 M)(254.3 M)(342 M)(337.7 M)(354.6 M)
RCUS(18 M)(18 M)(18 M)(18 M)(18 M)(18 M)(18 M)(53.1 M)(49.6 M)(75.9 M)(116.7 M)53 M(267 M)(307 M)(283 M)(268.9 M)
KURA(33.6 K)(22.4 K)(27 K)(27.3 K)(11 M)(22.6 M)(27.6 M)(35.4 M)(60.4 M)(63.1 M)(89.4 M)(129.9 M)(136.1 M)(152.6 M)(174 M)(165.3 M)
PTGX(11.1 M)(11.1 M)(11.1 M)(11.1 M)(11.1 M)(14.9 M)(37.2 M)(37 M)(38.9 M)(77.2 M)(66.2 M)(122.6 M)(123.4 M)(79 M)275.2 M288.9 M
MRUS(13.7 M)(13.7 M)(13.7 M)(13.7 M)(21.2 M)(25.3 M)(49.7 M)(87.7 M)(27.8 M)(55.2 M)(85.5 M)(66.8 M)(131.2 M)(154.9 M)(215.3 M)(204.6 M)
REPL(7.7 M)(7.7 M)(7.7 M)(7.7 M)(7.7 M)(7.7 M)(7.7 M)(19.7 M)(30.8 M)(52.6 M)(80.9 M)(118 M)(174.3 M)(215.8 M)(194.2 M)(184.5 M)
PLRX(30.3 M)(30.3 M)(30.3 M)(30.3 M)(30.3 M)(30.3 M)(30.3 M)(30.3 M)(30.3 M)185 K(39.7 M)(17.9 M)(121.5 M)(161.3 M)(210.3 M)(199.8 M)
SNDX(10 M)(10 M)(10 M)(14.2 M)(19.8 M)(24.1 M)(44.5 M)(60.8 M)(74 M)(56 M)(73.1 M)24.9 M(143.7 M)(209.4 M)(318.8 M)(302.8 M)
RVMD(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(41.8 M)(47.7 M)(108.2 M)(179.8 M)(248.7 M)(436.4 M)(600.1 M)(570.1 M)
VRDN(7.2 M)(7.2 M)(7.2 M)(2.2 M)(7.9 M)(11.3 M)(12.7 M)(26.5 M)(32.7 M)(42.4 M)(111 M)(79.4 M)(125.4 M)(237.7 M)(269.9 M)(256.5 M)

Mersana Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Mersana Therapeutics financial statement analysis. It represents the amount of money remaining after all of Mersana Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Mersana Therapeutics Competitive Analysis

The better you understand Mersana Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mersana Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mersana Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MRSN TERN AMLX ABOS INZY XFOR DAWN HOOK CGEM RLAY
 2.22 
 0.46 
Mersana
 7.83 
 3.18 
Terns
 1.09 
 3.63 
Amylyx
 3.28 
 1.26 
Acumen
 7.41 
 1.00 
Inozyme
 6.25 
 0.34 
XFOR
 6.67 
 8.12 
Day
 6.40 
 1.17 
Hookipa
 1.46 
 8.79 
Cullinan
 7.33 
 3.66 
Relay
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Equity Positions Weight
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Mersana Therapeutics Competition Performance Charts

Five steps to successful analysis of Mersana Therapeutics Competition

Mersana Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mersana Therapeutics in relation to its competition. Mersana Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mersana Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mersana Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mersana Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mersana Therapeutics position

In addition to having Mersana Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Shipbuilding Railroad Equipment Thematic Idea Now

Shipbuilding Railroad Equipment
Shipbuilding Railroad Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Shipbuilding Railroad Equipment theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Shipbuilding Railroad Equipment Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:
Check out Mersana Therapeutics Correlation with its peers.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Revenue Per Share
0.33
Quarterly Revenue Growth
0.529
Return On Assets
(0.25)
Return On Equity
(5.05)
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.